The timing of using IVIG for neonatal ABO hemolytic disease.

ABSTRACT:

Background

ABO hemolytic disease of the newborn (ABO HDN) is the most prevalent cause of hemolytic disease of the newborn, often leading to hyperbilirubinemia. In some cases, ABO HDN can progress to significant hyperbilirubinemia. The role of intravenous immunoglobulin (IVIG) in treating ABO HDN remains controversial. Several key questions regarding significant hyperbilirubinemia remain unanswered: What are the risk factors of ABO HDN with significant hyperbilirubinemia? Can IVIG provide benefits for ABO HDN with significant hyperbilirubinemia? Where do we place IVIG in the treatment sequence paradigm of ABO HDN? How do we best stratify ABO HDN with significant hyperbilirubinemia for IVIG therapy?

Methods

We conducted a retrospective cohort study include 948 newborns from We

SUBMITTER: Ma N 

PROVIDER: S-EPMC12492713 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature